Related Experiment Video
Updated: Feb 14, 2026

Characterizing Herbivore Resistance Mechanisms: Spittlebugs on Brachiaria spp. as an Example
Published on: June 19, 2011
Heterogeneity-based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report
Yutao Liu1, Xuezhi Hao1, Xingsheng Hu1
1Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Abstract:
Osimertinib is a novel, irreversible, mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR mutations and the EGFR T790 mutation. Here, we report a woman with EGFR-mutated lung adenocarcinoma who, after 23-month treatment with gefitinib, developed the EGFR T790M mutation, which converted the T790M status from positive to negative before osimertinib treatment and developed MET amplification, leading to rapid progression on osimertinib in two months. Subsequent treatment with crizotinib and c-Met inhibitor plus gefitinib also failed to improve the clinical outcome, suggesting the potential existence of another resistance mechanism. Our findings revealed the underlying multiple and heterogeneous mechanisms in resistance to osimertinib, suggesting combination strategies should be considered post-osimertinib progression.
Insights
This study details a patient with EGFR-mutated lung adenocarcinoma who developed resistance to osimertinib due to MET amplification. Multiple resistance mechanisms highlight the need for combination therapies after osimertinib progression.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR mutations.
- Gefitinib is a first-generation EGFR inhibitor used in treating EGFR-mutated lung adenocarcinoma.
Observation:
- A patient with EGFR-mutated lung adenocarcinoma developed resistance to osimertinib after initial gefitinib treatment.
- The patient experienced rapid progression on osimertinib due to MET amplification, despite initial T790M mutation negativity.
Findings:
- The study identified multiple and heterogeneous mechanisms of resistance to osimertinib.
- MET amplification was a key factor in osimertinib resistance, leading to treatment failure.
Implications:
- Combination strategies may be necessary to overcome osimertinib resistance in EGFR-mutated lung adenocarcinoma.
- Understanding diverse resistance mechanisms is crucial for optimizing lung cancer treatment.
More Related Videos
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
08:48Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis
Published on: January 29, 2016
Related Concept Videos
Data Reporting and Recording
Resistivity
Resistance
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:
Reaction Mechanisms
For instance, the decomposition of ozone appears to follow a mechanism with two steps:
Multiple Allele Traits